Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis
Seminars in Thrombosis and Hemostasis · 2026-04 · 52 (03) · 349-358
DOI: 10.1055/a-2788-1642 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 28.01.2026. Verfasst von Ilenia Calcaterra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Federico II University, Naples, Italy. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Acquired Hemophilia A (AHA) is a rare bleeding disorder caused by factor VIII inhibitors. Standard therapies are limited by thrombotic risk and prolonged hospitalization. Emicizumab, approved for congenital Hemophilia A, has emerged as a potential alternative in AHA based on case reports and early clinical trial data. To evaluate the efficacy and safety of Emicizumab in AHA through a retrospective real-world case series and a systematic literature review with patient-level data analysis. We retrospectively analyzed five AHA cases treated with Emicizumab at two Italian centers and performed a PRISMA-compliant systematic review of published reports, extracting and analyzing patient-level data using Joanna Briggs Institute tools. In the real-world cohort, early Emicizumab use in five patients with high-titer inhibitors and severe bleeding led to rapid hemorrhagic control, early withdrawal of bypassing agents, and no thrombotic or adverse events. All five patients received immunosuppression, and inhibitor eradication was achieved in 60% of patients, but for 40% follow up is still ongoing. The literature review identified 24 patients from 18 publications. Early Emicizumab administration (at admission) was associated with reduced bleeding recurrence (0% vs. 56.3%), shorter in-hospital stay (median 23.5 days vs. 39 days), and lower bleeding-related mortality (0% vs. 12.5%) compared with delayed administration. Early Emicizumab initiation appears to be a safe and effective strategy for AHA management, particularly in fragile or high-risk populations. Its subcutaneous route, favorable safety profile, and ability to reduce hospitalization support its integration into first-line therapeutic algorithms. Further prospective studies are warranted to define.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Federico II University, Naples, Italy.
- Centre for Congenital Haemorrhagic Disorders and Thrombotic Diseases, Rheumatologic and Immunologic Clinic, San Giovanni di Dio and Ruggi D'Aragona University Hospital, Salerno, Italy.
ORCID-Profile: Ilenia Calcaterra
Zitieren
APA
Calcaterra, I., De Luca, C., D'Errico, G., Miele, C., Caputo, C., Russo, R., Conca, P., Cimino, E., Guida, A., Tufano, A., & Minno, M. D. (2026). Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis. Seminars in Thrombosis and Hemostasis, 52(03), 349-358. https://doi.org/10.1055/a-2788-1642
Vancouver
Calcaterra I, De Luca C, D'Errico G, Miele C, Caputo C, Russo R, et al. Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis. Seminars in Thrombosis and Hemostasis. 2026;52(03):349-358. doi:10.1055/a-2788-1642
BibTeX
@article{Calcaterra2026,
author = {Calcaterra, Ilenia and De Luca, Carmine and D'Errico, Guido and Miele, Ciro and Caputo, Chiara and Russo, Raffaele and Conca, Paolo and Cimino, Ernesto and Guida, Anna and Tufano, Antonella and Minno, Matteo Di},
title = {Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {03},
pages = {349--358},
doi = {10.1055/a-2788-1642}
}
EUVIMED